BioCentury | Jan 6, 2021
Finance

Senti banks $105M series B as Bayer continues to show enthusiasm for gene and cell therapy biotechs

...could align strategically with the pharma’s future priorities.Other new investors in the series B included Matrix Partners China...
BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

...round led by RTW Investments and GT Fund with participation by existing investors CBC Group, Matrix Partners China...
BioCentury | Dec 9, 2020
Emerging Company Profile

How D3 Bio is building its biomarker-driven pipeline

...a syndicate of investors including Boyu Capital, Matrix Partners China...
...employees: UndisclosedFunds raised: $200 millionInvestors: Boyu Capital, Matrix Partners China...
BioCentury | Dec 9, 2020
Emerging Company Profile

Tallac: linking antibodies to DNA-triggered innate immunity

...round included venBio Partners, Morningside Venture, Lightstone Ventures, Matrix Partners China...
...millionInvestors: venBio Partners, Morningside Venture, Lightstone Ventures, Matrix Partners China...
BioCentury | Nov 17, 2020
Finance

D3 Bio’s debut with $200M series A highlights China’s fast-track to global stage

...$200 million series A round Tuesday backed by a syndicate of investors including Boyu Capital, Matrix Partners China...
BioCentury | Oct 29, 2020
Finance

Oct. 28 Quick Takes: Mirati raises $800M on KRAS data; BMS-insitro, Novartis-Molecular Partners, Genecast, Gracell, PureTech, Cerevel, Biodesix

...affiliate GL Ventures, Suzhou Zhongmengxin, Huaxing Capital and previous investors including China Capital Investment Group, Matrix Partners China...
BioCentury | Oct 6, 2020
Deals

Oct. 5 Quick Takes: BridgeBio reacquiring Eidos, Amgen KRAS data, after-hours tumbles for Iovance, Y-mAbs and more

...round co-led by Tencent, GL Ventures and YF Capital with participation by Morningside Venture Capital, Matrix Partners China...
BioCentury | Apr 17, 2020
Emerging Company Profile

Rgenta: enhancing interactions between RNA and RNA-binding proteins

...partners: N/A Number of employees: 6 Funds raised: $20 million Investors: Boehringer Ingelheim Venture Fund, Matrix Partners China...
BioCentury | Apr 3, 2020
Product Development

April 2 Quick Takes: Horizon takes out Curzion; plus Rgenta, Merck, Novartis-Aurobindo, Kite, Teneobio and Seattle Genetics

...Rgenta Therapeutics announced a $20 million seed round led by Boehringer Ingelheim Venture Fund and Matrix Partners China...
BioCentury | Nov 7, 2019
Financial News

Nov. 6 Financial Quick Takes: NEA backs Shape's series A; plus Royalty-Eisai-Epizyme, Sinomed, Genecast and Cadence

...first tranche of a series D round led by CICC Capital. Cowin Venture, Yahui Investment, Matrix Partners China...
Items per page:
1 - 10 of 18
BioCentury | Jan 6, 2021
Finance

Senti banks $105M series B as Bayer continues to show enthusiasm for gene and cell therapy biotechs

...could align strategically with the pharma’s future priorities.Other new investors in the series B included Matrix Partners China...
BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

...round led by RTW Investments and GT Fund with participation by existing investors CBC Group, Matrix Partners China...
BioCentury | Dec 9, 2020
Emerging Company Profile

How D3 Bio is building its biomarker-driven pipeline

...a syndicate of investors including Boyu Capital, Matrix Partners China...
...employees: UndisclosedFunds raised: $200 millionInvestors: Boyu Capital, Matrix Partners China...
BioCentury | Dec 9, 2020
Emerging Company Profile

Tallac: linking antibodies to DNA-triggered innate immunity

...round included venBio Partners, Morningside Venture, Lightstone Ventures, Matrix Partners China...
...millionInvestors: venBio Partners, Morningside Venture, Lightstone Ventures, Matrix Partners China...
BioCentury | Nov 17, 2020
Finance

D3 Bio’s debut with $200M series A highlights China’s fast-track to global stage

...$200 million series A round Tuesday backed by a syndicate of investors including Boyu Capital, Matrix Partners China...
BioCentury | Oct 29, 2020
Finance

Oct. 28 Quick Takes: Mirati raises $800M on KRAS data; BMS-insitro, Novartis-Molecular Partners, Genecast, Gracell, PureTech, Cerevel, Biodesix

...affiliate GL Ventures, Suzhou Zhongmengxin, Huaxing Capital and previous investors including China Capital Investment Group, Matrix Partners China...
BioCentury | Oct 6, 2020
Deals

Oct. 5 Quick Takes: BridgeBio reacquiring Eidos, Amgen KRAS data, after-hours tumbles for Iovance, Y-mAbs and more

...round co-led by Tencent, GL Ventures and YF Capital with participation by Morningside Venture Capital, Matrix Partners China...
BioCentury | Apr 17, 2020
Emerging Company Profile

Rgenta: enhancing interactions between RNA and RNA-binding proteins

...partners: N/A Number of employees: 6 Funds raised: $20 million Investors: Boehringer Ingelheim Venture Fund, Matrix Partners China...
BioCentury | Apr 3, 2020
Product Development

April 2 Quick Takes: Horizon takes out Curzion; plus Rgenta, Merck, Novartis-Aurobindo, Kite, Teneobio and Seattle Genetics

...Rgenta Therapeutics announced a $20 million seed round led by Boehringer Ingelheim Venture Fund and Matrix Partners China...
BioCentury | Nov 7, 2019
Financial News

Nov. 6 Financial Quick Takes: NEA backs Shape's series A; plus Royalty-Eisai-Epizyme, Sinomed, Genecast and Cadence

...first tranche of a series D round led by CICC Capital. Cowin Venture, Yahui Investment, Matrix Partners China...
Items per page:
1 - 10 of 18